Email Us
View Reports

Geriatric Medicines Market

Geriatric Medicines Market Analysis - By Therapeutic Category (Analgesics, Antihypertensive, Statins, Antidiabetics, Proton Pump Inhibitor, Anticoagulant, Antipsychotic, and Antidepressant); By Therapeutic Conditions (Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, and Respiratory), By Regions (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) - Size, Share, Growth and Global Forecast to 2026

  • ID : 91557700  |  
  • Published : Jan-2019  |  
  • Region : Global  |  
  • Pages : 110   |  
  • Publisher : Polaris Market Research

Geriatric Medicines Market Size:

The Global Geriatric Medicines Market Size is anticipated to reach over USD 1,157.34 billion by 2026 according to a new research report published by Research Cosmos.

Geriatric medicines also called geriatrics is a division of medicines associated with preventive, clinical, remedial, and social aspects of disease generally amongst people that are aged over 65 years or more. In response to the needs of an aging population, demand for geriatric medicines and appropriate cure has developed rapidly during the last decades. The proper medical care for geriatric patients across the range of ill health conditions includes co-morbid complications such as syncope, cerebral aging, and falls among others.

Growth Drivers and Restraints:

The global geriatric medicines market is majorly driven by the factor including a rise in geriatric populations. According to the Eurostat, the number of people aged 65 years and above is expected to reach 141 million by 2050 globally. In addition, the high market growth is expected on account of the increasing occurrence of numerous target disorders in the geriatric population, the demographic modification, the rising trend in lifestyle-associated risk aspects, and the considerably developed access to economic medicine across the developing and emerging regions. Continuous R&D activities commenced by key players and pharmaceutical companies to provide to the patient demand is expected to gain the significant outcomes during the forecast period. The increasing occurrence of chronic ailments, refining healthcare organization in emerging economies, increasing acceptance of medical tourism, government initiatives as well as support to provide timely care, and an increasing number of specialty clinics are some of the other factors driving of the geriatric medicines market. However, difficulties associated with drug compatibility, lack of patient involvement in clinical trials, and side effects associated with the medications are the factors hampering the market growth.

Geriatric Medicines Market - Leading Segments By Therapeutic Category, Therapeutic Condition, By Geography.

On the basis of therapeutic category, the global geriatric medicines market is segmented into Analgesics, Antihypertensive, Statins, Antidiabetics, Proton Pump Inhibitor, Anticoagulant, Antipsychotic, and Antidepressant. Pain as an indication is associated with old age and the middle age population unveils the high occurrence rate of pain related syndromes. Based on current trends and the demand for proper therapy, the market is anticipated to witness high growth for therapeutic conditions during the forecast period. On the basis of therapeutic conditions, the global geriatric medicines market is segmented into Cardiovascular, Arthritis, Neurological, Cancer, Osteoporosis, and Respiratory. In 2017, the cardiovascular disease is estimated to be the dominating segment primarily due to the high proliferation of several cardiac disorders such as coronary artery disease, stroke, and hypertension.

Geographical Presences of Geriatric Medicines Market

North America is estimated to dominate the global Geriatric Medicines Market. The existence of developed healthcare facilities, favorable reimbursement policies, and the easy availability of important as well as life-saving medicine have significantly enhanced the average life expectancy rates in North America. Moreover, the number of people that are over 65 to 70 years suffering several target ailments is increasing continually which is further anticipated to boost the geriatric medicines market during the forecast period.

Top Companies Leading the Market:

Some major key players in global Geriatric Medicines Market include GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., Eli Lilly and Company, Abbott Laboratories Inc., AstraZeneca plc, Merck & Company Inc., and Sanofi S.A. among others.

Detailed Segmentation of the Global Geriatric Medicines Market:

Geriatric Medicines Market - By Therapeutic Category:

  • Analgesics
  • Antihypertensives
  • Statins
  • Antidiabetics
  • Proton Pump Inhibitor
  • Anticoagulant
  • Antipsychotic
  • Antidepressant

Geriatric Medicines Market - By Therapeutic Condition:

  • Cardiovascular
  • Arthritis
  • Neurological
  • Cancer
  • Osteoporosis
  • Respiratory

Geriatric Medicines Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Table of Contents

1. Overview and Scope

1.1. Research goal & scope

1.2. Research assumptions

1.3. Research Methodology

1.3.1. Primary data sources

1.3.2. Secondary data sources

1.4. Key takeaways

1.5. Stakeholders

2. Executive Summary

2.1. Market Definition

2.2. Market Segmentation

3. Geriatric Medicines Market Insights

3.1. Geriatric Medicines – Industry snapshot

3.2. Geriatric Medicines - Ecosystem analysis

3.3. Geriatric Medicines Market dynamics

3.3.1. Geriatric Medicines – Market Forces

3.3.1.1. Geriatric Medicines Market driver analysis

3.3.1.2. Geriatric Medicines Market restraint/challenges analysis

3.3.1.3. Geriatric Medicines Market opportunity analysis

3.4. Industry analysis - Porter's five force

3.4.1. Bargaining power of supplier

3.4.2. Bargaining power of buyer

3.4.3. Threat of substitute

3.4.4. Threat of new entrant

3.4.5. Degree of competition

3.5. Geriatric Medicines Market PEST analysis, 2017

3.5.1. Geriatric Medicines Industry trends

3.5.2. Competitive Ranking Analysis

4. Geriatric Medicines Market Size and Forecast by Therapeutic Category

4.1. Key findings

4.2. Analgesics

4.2.1. Global market estimates and forecasts, 2017 – 2026

4.3. Antihypertensives

4.3.1. Global market estimates and forecasts, 2017 – 2026

4.4. Statins

4.4.1. Global market estimates and forecasts, 2017 – 2026

4.5. Antidiabetics

4.5.1. Global market estimates and forecasts, 2017 – 2026

4.6. Proton Pump Inhibitor

4.6.1. Global market estimates and forecasts, 2017 – 2026

4.7. Anticoagulant

4.7.1. Global market estimates and forecasts, 2017 – 2026

4.8. Antipsychotic

4.8.1. Global market estimates and forecasts, 2017 – 2026

4.9. Antidepressant

4.9.1. Global market estimates and forecasts, 2017 – 2026

5. Geriatric Medicines Market Size and Forecast by Therapeutic Condition

5.1. Key findings

5.2. Cardiovascular

5.2.1. Global market estimates and forecasts, 2017 - 2026

5.3. Arthritis

5.3.1. Global market estimates and forecasts, 2017 – 2026

5.4. Neurological

5.4.1. Global market estimates and forecasts, 2017 – 2026

5.5. Cancer

5.5.1. Global market estimates and forecasts, 2017 - 2026

5.6. Osteoporosis

5.6.1. Global market estimates and forecasts, 2017 – 2026

5.7. Respiratory

5.7.1. Global market estimates and forecasts, 2017 – 2026

6. Geriatric Medicines Market Size and Forecast by Regions

6.1. Key findings

6.2. North America

6.2.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.2.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.2.3. U.S.

6.2.3.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.2.3.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.2.4. Canada

6.2.4.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.2.4.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.3. Europe

6.3.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.3.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.3.3. Germany

6.3.3.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.3.3.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.3.4. UK

6.3.4.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.3.4.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.3.5. France

6.3.5.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.3.5.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.3.6. Italy

6.3.6.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.3.6.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.4. Asia Pacific

6.4.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.4.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.4.3. China

6.4.3.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.4.3.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.4.4. India

6.4.4.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.4.4.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.4.5. Japan

6.4.5.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.4.5.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.4.6. Australia

6.4.6.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.4.6.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.5. Latin America

6.5.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.5.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.5.3. Brazil

6.5.3.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.5.3.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.5.4. Mexico

6.5.4.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.5.4.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

6.6. Middle East & Africa

6.6.1. Geriatric Medicines Market by Therapeutic Category, 2017 - 2026

6.6.2. Geriatric Medicines Market by Therapeutic Condition, 2017 - 2026

7. Company Profiles

7.1. GlaxoSmithKline Plc

7.1.1. Overview

7.1.2. Financials

7.1.3. Product Benchmarking

7.1.4. Recent Developments

7.2. BoehringerIngelheim GmbH

7.2.1. Overview

7.2.2. Financials

7.2.3. Product Benchmarking

7.2.4. Recent Developments

7.3. Novartis AG

7.3.1. Overview

7.3.2. Financials

7.3.3. Product Benchmarking

7.3.4. Recent Developments

7.4. Bristol-Myers Squibb Company

7.4.1. Overview

7.4.2. Financials

7.4.3. Product Benchmarking

7.4.4. Recent Developments

7.5. Pfizer, Inc.

7.5.1. Overview

7.5.2. Financials

7.5.3. Product Benchmarking

7.5.4. Recent Developments

7.6. Eli Lilly and Company

7.6.1. Overview

7.6.2. Financials

7.6.3. Product Benchmarking

7.6.4. Recent Developments

7.7. Abbott Laboratories Inc.

7.7.1. Overview

7.7.2. Financials

7.7.3. Product Benchmarking

7.8. AstraZeneca plc

7.8.1. Overview

7.8.2. Financials

7.8.3. Product Benchmarking

7.8.4. Recent Developments

7.9. Merck & Company Inc.

7.9.1. Overview

7.9.2. Financials

7.9.3. Product Benchmarking

7.9.4. Recent Developments

7.10. Sanofi S.A.

7.10.1. Overview

7.10.2. Financials

7.10.3. Product Benchmarking

7.10.4. Recent Developments

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?